Individualization of Ganciclovir and Valganciclovir Doses in Renal Transplant Patients for Prophylaxis or Treatment of Cytomegalovirusc (CMV) Infection Using Bayesian Prediction.

Trial Profile

Individualization of Ganciclovir and Valganciclovir Doses in Renal Transplant Patients for Prophylaxis or Treatment of Cytomegalovirusc (CMV) Infection Using Bayesian Prediction.

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Mar 2015

At a glance

  • Drugs Ganciclovir (Primary) ; Valganciclovir (Primary)
  • Indications Cytomegalovirus infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 26 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Mar 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 21 Mar 2012 Planned end date changed from 1 Jul 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top